Profound Medical Corp (PROF) Stock Price, Quote & News

Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or phys...

Industry: Medical Devices

Sector: Healthcare

Phone: 647 476 1350

Fax: 647 847 3739

Website: www.profoundmedical.com

Address:

2400 Skymark Avenue, Unit 6, Mississauga, Canada

NVDAMillionaire Sep. 29 at 3:52 PM

$PROF Outstanding article that hits the mark on PROF's current state. So if you want to refresh your PROF insights or learn about PROF from scratch, this is a must read. https://beyondspx.com/quote/PROF/analysis/profound-medical-s-precision-ablation-ignites-mainstream-prostate-care-expansion-nasdaq-prof

2 · Reply

StockScanners Sep. 25 at 1:26 AM

$PROF reached 5.56

0 · Reply

StockScanners Sep. 24 at 1:37 AM

$PROF keep watch if this holds above 4.85

0 · Reply

FinancialScience Sep. 23 at 11:57 PM

$PROF https://texasprostate.com/sumbul-shaikh/

0 · Reply

DSWN Sep. 23 at 11:03 PM

$PROF On a technical side , five year trend channel resistance at $9.10. Then Fibo at 11.91 Let’s just say, I hope we blow through that

0 · Reply

QES Sep. 23 at 1:24 PM

$PROF The program is notable for several reasons: It specifically enables Medicare-covered patients to receive the TULSA procedure for both prostate cancer and benign prostatic hyperplasia (BPH) Same-day, minimally invasive treatment with no overnight hospital stay, no procedural blood loss, and a significantly lower risk of side effects like incontinence or erectile dysfunction compared to traditional surgery It demonstrates a novel business model where a private urology practice collaborates with a hospital to deliver this advanced treatment, creating a template that could be replicated nationwide to improve access to state-of-the-art prostate care for Medicare patients.

0 · Reply

RFL2 Sep. 22 at 10:31 PM

$PROF anyone have an idea about why the incredibly high volume today? Didn't help the stock but maybe it put in the bottom

2 · Reply

johntarlick Sep. 21 at 1:28 PM

$PROF well i was curious if any of the insiders had bought on the recent dip, as they had done on the similar dip back in the spring. Turns out 3 of the 4 did so again this time, but one did not and that one was, unexpectedly, the CCO. The guy who is under the gun to deliver the goods, right here, right now. And who has strongly asserted he's got dozens of virtually complete sales that will finalize before 2026. One good quarterly report, which will also be the first ever good quarterly report, ought to blow the lid off the stock price and that dip was a golden buying opportunity.

2 · Reply

Bigskies Sep. 20 at 6:53 PM

$PROF This is the time for management to step up and grow the business. I trust that they are getting the equipment installed and promoting its use. Nothing holding them back.

0 · Reply

johntarlick Sep. 12 at 2:02 PM

$PROF hmmm not sure what just happened this week, another lurch. I hesitate to table this, and it's usually just background noise, but the reviews over on glassdoor have recently taken a similar lurch. Sour grapes is one thing, but there is a theme that shows consistently through on almost every single review, and that is, it's great technology. Everyone that has worked on it, has understood it and has liked it.

0 · Reply

Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment

Aug 28, 2025, 8:00 AM EDT - 5 weeks ago

Profound Medical to Participate in Lake Street's 9th Annual Best Ideas Growth Conference

Aug 18, 2025, 7:01 PM EDT - 6 weeks ago

Profound Medical: Smokes Is Everywhere, Initiate At Sell

Aug 14, 2025, 9:24 PM EDT - 7 weeks ago

Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript

PRN

Aug 14, 2025, 4:05 PM EDT - 7 weeks ago

Profound Medical Announces Second Quarter 2025 Financial Results

Jul 24, 2025, 5:00 PM EDT - 2 months ago

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

May 14, 2025, 4:45 PM EDT - 5 months ago

Profound Medical Annual General and Special Meeting of Shareholders Voting Results

May 9, 2025, 7:17 AM EDT - 5 months ago

Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript

Apr 30, 2025, 4:30 PM EDT - 5 months ago

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 29, 2025, 7:30 AM EDT - 5 months ago

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Apr 15, 2025, 7:45 AM EDT - 6 months ago

Profound Medical AUA 2025 Investor Event Agenda

Apr 8, 2025, 10:00 AM EDT - 6 months ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 8, 2025, 9:32 AM EDT - 6 months ago

PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm

Apr 7, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation

Apr 6, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect

Apr 4, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Shareholders to Reach Out

Apr 3, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the Investigation

Apr 2, 2025, 10:00 AM EDT - 6 months ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Investors to Connect

Mar 31, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities Investigation

Mar 28, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation

Mar 27, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation

Mar 26, 2025, 9:59 PM EDT - 6 months ago

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws

Mar 26, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out

Mar 25, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out

Mar 24, 2025, 1:00 PM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect

Mar 6, 2025, 8:35 PM EST - 7 months ago

Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript

Feb 13, 2025, 5:00 PM EST - 8 months ago

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Jan 8, 2025, 7:30 AM EST - 9 months ago

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Jan 6, 2025, 8:15 AM EST - 9 months ago

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 9:55 AM EST - 10 months ago

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Dec 6, 2024, 9:04 AM EST - 10 months ago

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Dec 5, 2024, 4:48 PM EST - 10 months ago

Profound Medical Announces Proposed Public Offering of Common Shares

Dec 2, 2024, 7:30 AM EST - 10 months ago

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Nov 26, 2024, 7:45 AM EST - 11 months ago

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant'

Nov 10, 2024, 8:50 AM EST - 11 months ago

Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 6:55 AM EST - 11 months ago

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

Oct 16, 2024, 4:15 PM EDT - 1 year ago

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Profound Medical to Participate in Lake Street's Best Ideas Growth Conference

Aug 8, 2024, 11:11 PM EDT - 1 year ago

Profound Medical Corporation (PROF) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 4:30 PM EDT - 1 year ago

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

May 15, 2024, 5:00 PM EDT - 1 year ago

Profound Medical Annual General Meeting of Shareholders Voting Results

May 14, 2024, 7:30 AM EDT - 1 year ago

Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan

May 11, 2024, 1:47 PM EDT - 1 year ago

Profound Medical Corp. (PROF) Q1 2024 Earnings Call Transcript

NVDAMillionaire Sep. 29 at 3:52 PM

2 · Reply

StockScanners Sep. 25 at 1:26 AM

$PROF reached 5.56

0 · Reply

StockScanners Sep. 24 at 1:37 AM

$PROF keep watch if this holds above 4.85

0 · Reply

FinancialScience Sep. 23 at 11:57 PM

$PROF https://texasprostate.com/sumbul-shaikh/

0 · Reply

DSWN Sep. 23 at 11:03 PM

$PROF On a technical side , five year trend channel resistance at $9.10. Then Fibo at 11.91 Let’s just say, I hope we blow through that

0 · Reply

QES Sep. 23 at 1:24 PM

0 · Reply

RFL2 Sep. 22 at 10:31 PM

$PROF anyone have an idea about why the incredibly high volume today? Didn't help the stock but maybe it put in the bottom

2 · Reply

johntarlick Sep. 21 at 1:28 PM

2 · Reply

Bigskies Sep. 20 at 6:53 PM

$PROF This is the time for management to step up and grow the business. I trust that they are getting the equipment installed and promoting its use. Nothing holding them back.

0 · Reply

johntarlick Sep. 12 at 2:02 PM

0 · Reply

RFL2 Aug. 24 at 8:15 PM

$PROF the real drawback they don't talk about is a catheter for about a week. Am I wrong?

2 · Reply

SmartMoneyTradez Aug. 19 at 2:26 AM

$WALD $PROF

0 · Reply

johntarlick Aug. 17 at 1:10 PM

$PROF I'm inclined to give the benefit of the doubt on the pipeline. After all, management has been asked about the new installs 'pipeline' on just about every call for some years now, and has NEVER agreed to say what it was. In sharp contrast to that, the pipeline was here delivered as a veritable cold open. So I can't imagine those numbers aren't to some extent true. What really concerned me, is that the recurring revenue was up only 7% quarter over quarter. Aside from any issues on the pipeline, there are 60 installed sites and those sites need to be growing their business by more than 7% per year. What happened? None of the analysts asked.

1 · Reply

mlanthoo Aug. 16 at 3:28 PM

$PROF it seems this management team overpromises and underdelivers on an ongoing basis . time for new direction as current management isn't getting the job done . always an excuse .

0 · Reply

Basic_Trader01 Aug. 15 at 5:07 PM

$PROF the end is near, need for leadership change.

0 · Reply

johntarlick Aug. 8 at 12:29 PM

wow PCRT just imploded. i hadn't been following it closely and I had thought to move to pursue cancer clearance was generally correct. But apparently the stock price was run up out of all proportion to that opportunity, and that combined with c-suite churnover resulted in a meltdown. normally i wouldn't jump to conclusions, but I do think this opens the door for $PROF to pick up some new investors/attention.

1 · Reply

BioTuesdays Jul. 29 at 9:40 PM

Cook Medical’s launch of new iMRI division may help pave the way for wider and faster adoption of innovative procedures, like Profound’s TULSA $PROF https://biotuesdays.com/2025/07/29/cook-medicals-launch-of-new-imri-division-may-help-pave-the-way-for-wider-and-faster-adoption-of-innovative-procedures-like-profounds-tulsa/

4 · Reply

BioTuesdays Jul. 16 at 7:58 PM

Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical, reiterating his ‘buy’ rating and $11 target price on the company’s stock $PROF https://biotuesdays.com/2025/07/16/lake-street-sees-cmss-proposed-2026-tulsa-reimbursement-as-favorable/

1 · Reply

dndodd Jul. 14 at 11:44 AM

$PROF as a follow up to a friend I introduced to Tulsa. He chose Tulsa over DaVinci (which was scheduled). He is very happy with end result no surgery and his prostate is shrunk or gone. The only complications was he had to have a catheter a little longer than expected as they totally did away with the prostrate. He traveled 500 miles to go the Tulsa route. We have a great medical community in Birmingham, Al but someone needs to be the first to buy a Tulsa as I am sure it would be a success.

0 · Reply

johntarlick Jul. 13 at 12:06 PM

$PROF a strange business. Over on glassdoor, it's being said a round of layoffs in the sales team took effect on July 1. Not sure what to make of this. By my tally, the 2020-2024 sales team had never numbered more than about 20. But, since the new CCO came on board last fall, it had been publicly stated that he'd be getting a sales team of no less than 40. That hadn't seemed realistic to me, but i did at least appreciate the intent of going all in on driving sales and building revenue. Now it seems like that's being walked back a little.

0 · Reply

johntarlick Jul. 4 at 2:15 AM

another Canadian medtech with some parallels to $PROF (Synaptive) has just emerged from bankruptcy, with some new investment and an unknown future. Much like $PROF, they pioneered a new surgical tool with image-guidance. Like TulsaPro, the Synaptive exoscope was technically best in class. Like $PROF, Synaptive struggled to place many systems. Like $PROF, Synaptive was small and somewhat under-funded compared to the competition. To be clear, Synaptive made a certain mistake that $PROF has not made. Perhaps two. But still, Synaptive was loaded to the gills with talent. It had seemed just a few years ago that their future was bright.

0 · Reply

johntarlick Jun. 25 at 11:33 AM

not super new, but i only just caught it. the original founder of $PROF recently co-founded a boutique concierge prostate clinic to offer tulsaPRO in Texas. Interestingly, that clinic also offers HIFU. If the founder of $PROF thinks HIFU is still a viable choice, it nicely informs the comparative long term prospects for these two related technologies.

2 · Reply

Market Cap	170.94M
Revenue (ttm)	10.68M
Net Income (ttm)	-27.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-260.49%
Debt to Equity Ratio	0.11

Volume	58,700
Avg Vol	132,366
Day's Range	N/A - N/A
Shares Out	30.12M
Stochastic %K	88%
Beta	0.66
Analysts	Strong Sell
Price Target	$12.31